Crossmark

Basic principles of neuroimmunology

Crossref DOI link: https://doi.org/10.1007/s00281-022-00951-7

Published Online: 2022-06-22

Published Print: 2022-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yoshida, Tomomi M.

Wang, Andrew

Hafler, David A. https://orcid.org/0000-0003-4529-720X
Funding

Funding for this research was provided by:

National Institutes of Health (U19 AI089992)

National Institutes of Health (R25 NS079193)

National Institutes of Health (P01 AI073748)

National Institutes of Health (U24 AI11867)

National Institutes of Health (R01 AI22220)

National Institutes of Health (UM 1HG009390)

National Institutes of Health (P01 AI039671)

National Institutes of Health (P50 CA121974)

National Institutes of Health (R01 CA227473)

National Institutes of Health (K08 AI128745)

National Institutes of Health (R01 AI162645)

National Institutes of Health (5T32 AI 007019-46)

National Multiple Sclerosis Society (CA 1061- A-18)

National Multiple Sclerosis Society (RG-1802-30153)

Nancy Taylor Foundation for Chronic Diseases

Race to Erase MS

Pew Charitable Trusts

Richard and Susan Smith Family Foundation
License Information

Text and Data Mining valid from 2022-06-22

Version of Record valid from 2022-06-22
More Information

Article History

Received: 3 December 2021

Accepted: 8 May 2022

First Online: 22 June 2022

Declarations

:

: D. A. H. has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, and Genentech. He has been a consultant for Bayer Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Juno therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme. Further information regarding funding is available on

Document is current

Any future updates will be listed below